Articles By Jack Cush, MD
Early RA and the Chance of DMARD-Free Remission
Early and aggressive treatment of rheumatoid arthritis has become the mantra for most who manage the disease and hope to achieve optimal outcomes - including remission.
Read Article
BMI at Age 20 Influences Future Risk of Low Back Pain
A nationwide, cross-sectional study of men aged 30–50 years (n=1385) examined the relationship between weight and back pain over time.
Read Article
Fasenmyer Grant to Calabrese and Lederman Will Further the Interface Between Rheumatology and Virology
Two longtime collaborators studying HIV/AIDS at the Cleveland Clinic and Case Western Reserve University have received an $18.5 million grant from the Richard J. Fasenmyer Foundation.
Read Article
Rheumatology - the Favored Few
A routine visit, followed by a few post-visit comments from the familly, is all it takes to remind me how great it is to be a rheumatologist.
Read Article
Off-Label Use – A Free Speech, Scientific and Safety Issue
Is off-label drug use an example of "free speech"? Do off-label use guidelines affect every day practice or the way Pharma promotes its product outside of the indications for which it was approved?
Read Article
Epidural Steroid Injections Ineffective
A meta-analysis of 30 placebo-controlled trials evaluated epidural corticosteroid injections for radiculopathy, and 8 trials were done for spinal stenosis.
Read Article
Colon Cancer Risk Cut by Aspirin and NSAIDs
A population-based study from Northern Denmark studied the effects of aspirin and NSAIDs on colorectal cancer rates (Citation source http://buff.ly/1KJQ6H3).
Read Article
Secukinumab Bests Ustekinumab in Psoriasis CLEAR Study
The CLEAR study was a one-year, randomized, double-blind trial compared subcutaneous standard doses of secukinumab (anti-IL17) and ustekinumab (anti-IL12/23) in patients with moderate-severe plaque psoriasis.
Read Article
Amgen Agrees to $71 Million Settlement over Enbrel & Aranesp Promotion
Based on potentiallly off-label promotion of blockbuster drugs Aranesp and Enbrel, Amgen has agreed to a $71 million settlement with 48 states and the District of Columbia.
Read Article
Serious Infections are Increasing in Lupus
Tektonidou and coworkers have analyzed hospitalized serious infections (SIE) involving lupus patients over a 15 year period and show that SIE in SLE have increased substantially between 1996 and 2011, and in 2011 are 12 times higher than seen in patients without SLE.
Read Article
